Cargando…

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma

Detalles Bibliográficos
Autores principales:	Catalano, Martina, Nesi, Gabriella, Roviello, Giandomenico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Via Medica 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826649/ https://www.ncbi.nlm.nih.gov/pubmed/36632294 http://dx.doi.org/10.5603/RPOR.a2022.0119

Ejemplares similares

Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope?
por: Cosso, Federica, et al.
Publicado: (2023)

Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
por: Roviello, Giandomenico, et al.
Publicado: (2020)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Second line of treatment for HER2-positive gastric cancer: an evolving issue
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Comparison of Anti–Programmed Cell Death Ligand 1 Therapy Combinations vs Sunitinib for Metastatic Renal Cell Carcinoma: A Meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

DNA repair deficiency as circulating biomarker in prostate cancer
por: Catalano, Martina, et al.
Publicado: (2023)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Editorial: Microbiota and metabolites in cancer immunotherapy
por: Roviello, Giandomenico, et al.
Publicado: (2022)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer
por: Catalano, Martina, et al.
Publicado: (2020)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers
por: Kaźmierczak-Siedlecka, Karolina, et al.
Publicado: (2021)

Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas
por: Catalano, Martina, et al.
Publicado: (2021)

The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
por: Catalano, Martina, et al.
Publicado: (2022)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

Cetuximab Related Eyelash Elongations for Patients with Metastatic Rectum Carcinoma: Metabolic Complete Response
por: Ürün, Yüksel, et al.
Publicado: (2013)

Undergraduate research in India hoping for a new dawn
por: Chatterjee, Krishnarpan, et al.
Publicado: (2016)

Old drug fluvoxamine, new hope for COVID-19
por: Hashimoto, Yaeko, et al.
Publicado: (2021)

Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors
por: Catalano, Martina, et al.
Publicado: (2022)

Long lasting complete response with immunotherapy in a metastatic bladder carcinoma: a case report
por: Magalhães, Denise S.T., et al.
Publicado: (2021)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Inflammation in Urological Malignancies: The Silent Killer
por: Catalano, Martina, et al.
Publicado: (2023)

Polymyxin-B Combination Therapy – A Dire Need to Safeguard Our Last Hope
por: Lakhe, Maheshkumar, et al.
Publicado: (2016)

Hemisection-hope for last survival
por: Hasija, Mukesh, et al.
Publicado: (2013)

Long-term survival in a case of metastatic papillary renal cell carcinoma
por: Essam, Abdul Monem, et al.
Publicado: (2017)

REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
por: Lavacchi, Daniele, et al.
Publicado: (2020)

NEW HOPE FOR HIV/AIDS PATIENTS: THE CASE OF A SUDANESE ADULT PATIENT
por: Zeidan, Z.A., et al.
Publicado: (2002)

Hope Hospital
por: Taylor, J. H.
Publicado: (1909)

High Hopes ... for General (Internal) Medicine
por: Gray, David
Publicado: (1994)

Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Association of intrinsic pathways with altered tumor immune infiltration in hepatocellular carcinoma: New targets for combining immune therapy
por: Chen, Zheng, et al.
Publicado: (2020)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Roxadustat for SARS-CoV-2 Infection: Old Signaling Raised New Hopes
por: Alkazmi, Luay, et al.
Publicado: (2022)

Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Porta, C
Publicado: (2010)

Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
por: Charbonneau, C, et al.
Publicado: (2010)

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
por: Mickisch, G H J, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_iq4045d0s8vfirk806ievhe65a